<DOC>
	<DOCNO>NCT00005866</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . It yet know total-body irradiation plus peripheral stem cell transplantation effective busulfan cyclophosphamide myelodysplastic syndrome acute myeloid leukemia . PURPOSE : Randomized phase III trial compare effectiveness busulfan cyclophosphamide patient undergo total-body irradiation plus peripheral stem cell transplantation advance myelodysplastic syndrome relate acute myeloid leukemia .</brief_summary>
	<brief_title>S9920 Busulfan Compared With Cyclophosphamide Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation Advanced Myelodysplastic Syndrome Related Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare event free survival total body irradiation ( TBI ) plus busulfan versus TBI plus cyclophosphamide follow allogeneic peripheral blood stem cell transplantation patient advance myelodysplastic syndrome ( MDS ) MDS relate acute myeloid leukemia . II . Determine distribution pharmacokinetic parameter busulfan patient randomized busulfan treatment arm . III . Investigate prognostic significance event free survival prior history red cell transfusion , cytogenetic pattern , functional drug resistance diagnosis patient . IV . Estimate frequency cytogenetic genetic change disease progression patient . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 40 vs 41-55 ) diagnosis International Prognostic Scoring System ( IPSS ) risk group ( myelodysplastic syndrome ( MDS ) /IPSS - intermediate 1 v MDS/IPSS - intermediate 2 v MDS/IPSS high risk v MDS relate acute myeloid leukemia ) . Patients randomize one two treatment arm . Arm I : Patients receive busulfan IV 2 hour every 6 hour day -7 -4 total 16 dos . Arm II : Patients receive cyclophosphamide IV 2 hour day -5 -4 . Patients receive total body irradiation ( TBI ) twice day day -3 -1 ; peripheral blood stem cell transplantation genotypically HLA identical sibling day 0 ; cyclosporine IV every 12 hour day -1 60 , taper absence graft versus host disease ; methotrexate IV day 1 , 3 , 6 , 11 . Patients follow every 6 month 5 year . PROJECTED ACCRUAL : A total 240 patient ( 120 per treatment arm ) accrue study 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm myelodysplastic syndrome ( MDS ) Increased blast ( i.e. , great 1 30 % peripheral blood blast and/or 5 30 % bone marrow blast ) AND International Prognostic Score intermediate 1 , intermediate 2 , high risk Refractory anemia excess blast OR Refractory anemia excess blast transformation ( presence auer rod sole criterion ) OR Chronic myelomonocytic leukemia Greater 1 % blast peripheral blood and/or least 5 % blast bone marrow OR MDS relate acute myeloid leukemia Arising document MDS least 60 day Absolute peripheral blast count great 5,000/mm3 Must genotypically HLA identical sibling donor Must also enrol SWOGS9910 SWOG9007 PATIENT CHARACTERISTICS : Age : 16 55 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : No prior malignancy within past 5 year except : Adequately treat basal cell squamous cell skin cancer Carcinoma situ cervix Adequately treat stage I II cancer complete remission HIV negative Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No autologous peripheral stem cell transplantation prior diagnosis myelodysplastic syndrome ( MDS ) MDS relate acute myeloid leukemia Chemotherapy : No prior chemotherapy MDS MDS relate acute myeloid leukemia except oral chemotherapy control leukocytosis thrombocytosis ( e.g. , hydroxyurea etoposide ) Endocrine therapy : Not specify Radiotherapy : No radiotherapy prior diagnosis MDS MDS relate acute myeloid leukemia Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>